On the other hand, since part of the adaptation of prostate cancer to manipulation of the androgen environment is to increase heterogeneity of AR expression, it may be that any potential benefit of the testosterone flare is counterbalanced by the consequences of this first round of adaptation to the spike in testosterone levels that accompany the initial response to GnRH agonists. This evidence concerns the gene GNRH1 and Familial prostate cancer.